Clinical trial
The Efficacy and Safety of Postoperative Chemotherapy With Docetaxel Plus Oxaliplatin and Capecitabine Versus Oxaliplatin Plus Capecitabine for Postoperative Pathological Stage IIIB/IIIC Gastric Adenocarcinoma: a Randomised, Phase 3 Trial
NCT04351867 is registered in ClinicalTrials.gov with LiNing as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of Postoperative Chemotherapy With Docetaxel Plus Oxaliplatin and Capecitabine Versus Oxaliplatin Plus Capecitabine for Postoperative Pathological Stage IIIB/IIIC Gastric Adenocarcinoma: a Randomised, Phase 3 Trial
- Lead sponsor
- LiNing
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- September 30, 2020
- Completion date
- June 30, 2024
- Enrollment
- 196 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.